Resiko Efek Samping Perdarahan pada Penggunaan Fondaparinux (Arixtra) sebagai Antikoagulan: Kajian Literatur
DOI:
https://doi.org/10.31004/jptam.v5i3.3076Keywords:
Perdarahan, Fondaparinux, AntikoagulanAbstract
Perdarahan merupakan salah satu efek samping yang terjadi pada pasien yang menggunakan Antikoagulan. Artikel ini menyajikan beberapa bukti terkait efek samping perdarahan akibat penggunaan Fondaparinux sebagai Antikoagulan. Fondaparinux adalah obat pertama yang disetujui di antara penghambat faktor Xa secara selektif dibandingkan dengan LMWH. Penelitian ini dilakukan untuk melihat resiko efek samping perdarahan terhadap penggunaan Fondaparinux (Arixtra) sebagai Antikoagulan. Penelitian ini menggunakan metode review melalui database jurnal dengan kasus Resiko Efek Samping Perdarahan terhadap Penggunaan Fondaparinux (Arixtra). Fondaparinux memiliki efek samping berupa major bleeding karena merupakan antikoagulan yang merupakan inhibitor spesifik dari Faktor-Xa. Kejadian ini terjadi pada pasien yang menerima terapi antikoagulan untuk penyakit NSTEMI, IHT, dan ACS. Namun, terdapat mekanisme yang belum jelas terkait dengan major bleeding yang disebabkan oleh Fondaparinux sehingga perlu dilakukan penelitian lebih lanjut terkait hal tersebut.
References
Alsheikh, Khalid, Ahmed Hilabi, Abdulaziz Aleid, Khalid G. Alharbi, Hussam S. Al Angari, Mohammed Alkhamis, Faisal Alzahrani, and Wedad Madani. 2021. “Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery.” Cureus 13(11).
Brandao, Gustavo M. S., Daniela R. Junqueira, Hamilton A. Rollo, and Marcone L. Sobreira. 2015. “Pentasaccharides for the Treatment of Deep Vein Thrombosis.” Cochrane Database of Systematic Reviews 2015(7).
Bundhun, Pravesh Kumar, Musaben Shaik, and Jun Yuan. 2017. “Choosing between Enoxaparin and Fondaparinux for the Management of Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.” BMC Cardiovascular Disorders 17(1):1–13.
Cohen, Alexander T., Samantha E. Berger, Dušan Milenkovi?, Nathan R. Hill, and Steven Lister. 2019. “Anticoagulant Selection for Patients with VTE—Evidence from a Systematic Literature Review of Network Meta-Analyses.” Pharmacological Research 143(December 2018):166–77.
Hur, Min, Sun Kyung Park, Chang Hoon Koo, Eun Dhong Jung, Pyoyoon Kang, Won Ho Kim, Jin Tae Kim, Chul Woo Jung, and Jae Hyon Bahk. 2017. “Comparative Efficacy and Safety of Anticoagulants for Prevention of Venous Thromboembolism after Hip and Knee Arthroplasty: A Network Meta-Analysis.” Acta Orthopaedica 88(6):634–41.
Khan, M.Y., Ponde, C.K., Kumar, V., Gaurav, K., 2022. Fondaparinux: A cornerstone drug in acute coronary syndromes. World J. Cardiol. 14, 40–53. https://doi.org/10.4330/wjc.v14.i1.40
Kumar, Arun, Ashna Talwar, Joel F. Farley, Jagannath Muzumdar, Jon C. Schommer, Rajesh Balkrishnan, and Wenchen Wu. 2019. “Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-Analysis.” Journal of the American Heart Association 8(10).
Linkins, Lori Ann, George Hu, and Theodore E. Warkentin. 2018. “Systematic Review of Fondaparinux for Heparin-Induced Thrombocytopenia: When There Are No Randomized Controlled Trials.” Research and Practice in Thrombosis and Haemostasis 2(4):678–83.
Metwali, HendH, MohammedA Aseeri, Ahmed Mahmoud, AhmadS Alsaeed, MonaE Albdelwahab, Abdul Salam, and Rayf Abulezz. 2016. “Evaluation of Bleeding Risk in Patients with Renal Impairment Treated with Fondaparinux (Arixtra).” Journal of Applied Hematology 7(4):131.
Mohammed Yunus Khan, Chandrashekhar K Ponde, Viveka Kumar, Kumar Gaura. 2022. “Contents.” 8462(1).
Nilius, Henning, Jonas Kaufmann, Adam Cuker, and Michael Nagler. 2021. “Comparative Effectiveness and Safety of Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia.” American Journal of Hematology 96(7):805–15.
Nutescu, Edith A., Allison Burnett, John Fanikos, Sarah Spinler, and Ann Wittkowsky. 2017. “Pharmacology of Anticoagulants Used in the Treatment of Venous Thromboembolism.” Journal of Thrombosis and Thrombolysis 41(1):15–31.
Robiyatul, Siti, Ilham Alfiar, Nur Rahayuningsih, Calcium Channel Blocker, and Antagonis Aldosteron. 2021. “Kajian Interaksi Obat Aktual Pada Pasien Jantung Koroner Di Rumah Sakit x Kota Tasikmalaya.” 6(1):7–11.
Tandon, V., Khajuria, V., Mahajan, S., Mahajan, A., Sharma, S., 2013. A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml. J. -Life Health 4, 241. https://doi.org/10.4103/0976-7800.122260
Tokuhara, Katsuji, Hideyuki Matsushima, Yosuke Ueyama, Kazuyoshi Nakatani, Kazuhiko Yoshioka, and Masanori Kon. 2017. “Efficacy and Safety of Thromboembolism Prophylaxis with Fondaparinux in Japanese Colorectal Cancer Patients Undergoing Laparoscopic Surgery: A Phase II Study.” International Journal of Surgery 42:203–8.
Zhang, Zhi Hao, Jing Wen Zhang, Ping He, Yan Zhou, and Chang Yu Sun. 2017. “Fondaparinux Is Effective for Acute Portal Vein Thrombosis in Decompensated Cirrhotic Patients.” Medicine (United States) 96(42):1–5.
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2021 Anggoro Wicaksono, Sutriatmoko Sutriatmoko
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
